GlassScriptPhysician profile
Jacek Pieta
NPI 1821056540
$6,010.28
in general payments reported to CMS, 2019-2025
23 companies · $2,794 in 2025
The $2,794 reported for 2025 was more than what 82% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $590 · 2020: $146 · 2021: $245 · 2022: $18.39 · 2023: $433 · 2024: $1,784 · 2025: $2,794.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,994 · Education: $17.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,994.38 |
| Education | $17.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,933.47 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,729.93 | 2021-2025 | Tezspire, Breztri, Airsupra |
| Takeda Pharmaceuticals U.S.A., INC. | $255.52 | 2024-2025 | Glassia |
| Regeneron Healthcare Solutions, INC. | $212.34 | 2024-2025 | Dupixent |
| Genzyme Corporation | $199.80 | 2024-2025 | |
| Insmed, INC. | $185.98 | 2023-2025 | Arikayce |
| Genentech USA, INC. | $166.95 | 2019 | |
| Paratek Pharmaceuticals, INC. | $161.66 | 2023-2024 | Nuzyra |
| Baxter Healthcare | $153.97 | 2023-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System, Hillrom - Monarch Airway Clearance System |
| United Therapeutics Corporation | $147.03 | 2025 | Tyvaso |
| Actelion Pharmaceuticals US, INC. | $140.60 | 2025 | Uptravi, Opsumit |
| Verona Pharma, INC. | $136.26 | 2025 | Ohtuvayre |
| Lilly USA, LLC | $125.83 | 2025 | Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $101.88 | 2019-2025 | Ofev, Jascayd |
| Merck Sharp & Dohme LLC | $83.87 | 2024-2025 | Zerbaxa, Recarbrio |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $77.54 | 2024-2025 | Tezspire |
| Grifols USA, LLC | $74.38 | 2024-2025 | Prolastin-C Liquid |
| Mylan Specialty L.P. | $24.56 | 2024 | Yupelri |
| Inspire Medical Systems, INC. | $24.28 | 2025 | Inspire |
| Circassia INC. | $19.93 | 2019 | |
| Janssen Biotech, INC. | $18.39 | 2022 | |
| Inogen, INC. | $18.12 | 2025 | |
| Philips North America LLC | $17.99 | 2025 | Vest Therapy Und |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacek Pieta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.